Sectral
(Acebutolol)Phase 3Small molecule
Acebutolol is a medication that helps manage high blood pressure and irregular heartbeats by relaxing blood vessels and slowing down the heart rate, which improves blood flow and lowers blood pressure.[1] Sectral is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Sectral is one of 44 small molecule programs targeting Hemangioma. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
43
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Sectral
PPromius Pharma, LLC
Phase 3
Edarbi
TakedaPreclinical
Benicar
NovartisPreclinical
Apresoline
NovartisPreclinical
Zebeta
TevaPreclinical
Edarbi
TakedaPreclinical
Aceon
Institut de Recherches Internationales ServierPreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 28, 1984
SECTRAL
NDA NDA018917
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acebutolol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPromius Pharma, LLC